Phase 3 Study of STN1011402 ophthalmic cream in Patients With Seasonal Allergic Conjunctivitis

JRCT ID: jRCT2031220074

Registered date:19/05/2022

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Allergic Conjunctivitis
• Date of first enrollment: 24/06/2022
• Target sample size: 30
• Study type: Interventional
• Intervention(s): First, 30 mg of 0.5% STN1011402 ophthalmic cream or placebo ophthalmic cream will be applied once a day, next, antigen will be induced 24 hours after its application.

Outcome(s)

• Primary Outcome: Efficacy (Subjective Ocular Symptom Score and Objective Findings Score), Safety

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: < 65age old
• Gender: Both

Include criteria

Provided signed, written informed consent.
Has a positive result for from a Type I allergy test.

Exclude criteria

Eye disease other than allergic conjunctivitis is present and requires treatment.
Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception.

Related Information

• Primary Sponsor: Kayoko Sakamoto